Oral Semaglutide Reduces HbA1c and Body Weight in Patients With Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses
figure
posted on 2021-01-18, 11:24 authored by Adis journals on behalf of, Richard E. Pratley, Matthew J. Crowley, Mette Gislum, Christin L. Hertz, Thomas B. Jensen, Kamlesh Khunti, Ofri Mosenzon, John B. Buse<br><div><p><strong>Article
full text</strong></p>
<p><br>
The above summary slide and graphical abstract represent the opinions of
the authors. For a full list of declarations, including
funding and author disclosure statements, please see the full text online (see
“read the peer-reviewed publication” opposite). </p>
<p>© The authors, CC-BY-NC 2021.<b>
</b></p><br></div>
